The company is all set to launch new vaccines in the country, further strengthening the innovation landscape for vaccine R&D. Forum Bhagat, Managing Director of Novo Medi Sciences (Novo Group) spoke to BioSpectrum about the company's present and future plans. Edited excerpts:
What were the key highlights of the company in 2024? What are the major plans in store for 2025?
In 2024, we continued to expand our mission, considering that we must cater to critical healthcare challenges with innovative solutions. One of our recent key achievements, guided by the principles of our founder and my grandfather, late Ramesh C Bhagat, was the reintroduction of NEXICLOX DS 250mg, a trusted Cloxacillin syrup formulation.
This move addresses the dire need for effective treatments against critical infections like skin and soft tissue infections (SSTIs), osteomyelitis, respiratory tract infections (RTIs), and Endocarditis within the paediatric community. Initially launched in 1965, Cloxacillin is the gold-standard penicillin that was discontinued in the Indian pharmaceutical market for over 25 years. The rise of multi-drug resistance (MDR) has rendered many current combination molecules ineffective against susceptible Staphylococcus infections. Consequently, the medical fraternity emphasised the need for 'old is gold' standard molecules like Cloxacillin, which offers a lower likelihood of resistance due to its limited use in recent years.
By reintroducing NEXICLOX DS 250mg, we aim to provide healthcare professionals with a reliable and effective solution for treating critical infections in children, effective against MDR methicillin-susceptible Staphylococcus Aureus (MSSA) and has a low resistance risk with a proven safety profile.
This story is from the BioSpectrum India Jan 2025 edition of Bio Spectrum.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 9,000+ magazines and newspapers.
Already a subscriber ? Sign In
This story is from the BioSpectrum India Jan 2025 edition of Bio Spectrum.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 9,000+ magazines and newspapers.
Already a subscriber? Sign In
Sartorius Stedim Biotech opens new centre for bioprocess innovation in US
Sartorius Stedim Biotech, a leading partner of the biopharmaceutical industry, has opened its new centre for Bioprocess Innovation in Marlborough, Massachusetts in the US.
Agilent introduces innovative Mito-rOCR assay kit for mitochondrial research
Agilent Technologies Inc. has announced the new MitorOCR Assay Kit.
Qiagen launches AI-extension of Ingenuity Pathway Analysis for automatic interpretation of biological data
Qiagen has announced the launch of Ingenuity Pathway Analysis (IPA) Interpret, a new feature designed to simplify and accelerate the interpretation of complex biological data.
Parse Biosciences announces expansion of Evercode BCR product line
Parse Biosciences, a leader in scalable single cell sequencing solutions, has announced the expansion of its Evercode BCR product line to enable applications in mice.
New technology for unambiguous detection of HIV genome using tailored fluorogenic tests
A team of scientists at Jawaharlal Nehru Centre for Advanced Scientific Research (JNCASR), has developed a novel diagnostic technology known as the GQ Topology-Targeted Reliable Conformational Polymorphism (GQ-RCP) platform.
Gene mutation likely cause for developing autism in early childhood: RGCB study
Autism, a developmental disorder that causes functional abnormalities in brain development, is caused by a combination of environmental and genetic factors with its symptoms manifesting in childhood as early as the age of two years.
IIIT-Delhi unveils AI platform for discovering molecules that promote healthy ageing
A team of researchers from Indraprastha Institute of Information Technology Delhi (IIIT-Delhi) has developed AgeXtend, a groundbreaking artificial intelligence (AI)-based platform that is set to transform the search for molecules promoting healthy ageing.
RSSDI study lays focus on Yoga and Diabetes Prevention
Dr Jitendra Singh, Union Minister of State (Independent Charge) for Science and Technology, recently released the landmark study by Research Society for Study of Diabetes in India (RSSDI) on 'Yoga and Diabetes Prevention'.
Dr Alok Khullar steps in as Group CEO of RJ Corp Healthcare
RJ Corp Healthcare, a leading name in the healthcare sector through its renowned entities Cocoon Hospital and Cryoviva Stem Cell Bank, has announced the appointment of Dr Alok Khullar as Group Chief Executive Officer (CEO).
Entod Pharmaceuticals on-boards Dr Anish Desai as Scientific & Research adviser
Mumbai-based Entod Pharmaceuticals has appointed Dr Anish Desai as its Scientific and Research Adviser.
